Frontlight ResearchEarly access
Active, not recruitingNo phase
DCM Precision Medicine Study
Key facts
- Who runs it
- Ray Hershberger
- Where
- Ann Arbor, Atlanta, Baltimore, Beverly Hills, Birmingham, Boston, Charleston, Chicago, Cleveland, Columbus, Dallas, Fairfax, Houston, Jackson, Los Angeles, Miami, New Orleans, New York, Omaha, Palo Alto, Philadelphia, Salt Lake City, Seattle, St Louis, Tucson, and Washington D.C., United StatesSee the 26 sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 6,500 people, planned
- Started
- 7 Jun 2016
- Ended
- 30 Jun 2026
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- Family Heart Talk Booklet
- Record updated
- 30 July 2025
Who can take part
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- Meeting criteria for dilated cardiomyopathy (DCM) :; Left ventricular ejection fraction <50%; Left ventricular enlargement (A left ventricular end-diastolic dimension > 95%tile population standard based on gender and height)
- Detectable causes of cardiomyopathy, except genetic, excluded beyond a reasonable doubt at the time of DCM diagnosis (that is, meeting clinical criteria for idiopathic DCM)
- Any age (including children)
- Non-Hispanic and Hispanic ethnicity
- All races (PI pre-approval required for recruitment beyond pre-specified recruitment targets)
- Ability to give informed consent
- Ability to communicate in English (except Spanish language at sites approved to recruit individuals of Hispanic ethnicity)
- Willingness to participate in a family-based study (patient willing to work with a clinical site and/or OSU to facilitate the recruitment and enrollment of family members to the study)
Who cannot take part
- Adriamycin or other cardiotoxic drug exposure
- Coronary artery disease (CAD) causing ischemic cardiomyopathy (> 50% narrowing, any major epicardial coronary artery)
- Primary valvular disease
- Congenital heart disease
- Other active multi-system disease that may cause DCM (e.g., active connective tissue disease)
- Severe and untreated or untreatable hypertension (systolic blood pressures routinely greater than 180 mm Hg and/or diastolic blood pressures greater than 120 mm Hg, and if resistant to multidrug treatment)
- However, conventional risk factors for DCM, including obesity, routinely treated hypertension, alcohol use, pregnancy or the peri-partum period, or left ventricular noncompaction, will NOT be considered exclusion criteria
- Other forms of cardiomyopathy: Hypertrophic, Restrictive, or Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy
- Other detectable causes of dilated cardiomyopathy, including sarcoid and hemochromatosis
Where in United States
- University of MichiganAnn Arbor, United States
- Emory UniversityAtlanta, United States
- University of MarylandBaltimore, United States
- Cedars-Sinai Medical CenterBeverly Hills, United States
- University of Alabama at BirminghamBirmingham, United States
- Tufts Medical CenterBoston, United States
- Medical University of South CarolinaCharleston, United States
- Northwestern UniversityChicago, United States
- Cleveland ClinicCleveland, United States
- Ohio State UniversityColumbus, United States
- University of Texas Southwestern Medical CenterDallas, United States
- Inova Heart and Vascular InstituteFairfax, United States
- Houston Methodist HospitalHouston, United States
- University of Mississippi Medical CenterJackson, United States
- UCLA Medical CenterLos Angeles, United States
- South Miami Heart CenterMiami, United States
- Louisiana State University Health Sciences Center in New OrleansNew Orleans, United States
- NYU School of MedicineNew York, United States
- University of Nebraska Medical CenterOmaha, United States
- Stanford UniversityPalo Alto, United States
- University of PennsylvaniaPhiladelphia, United States
- University of UtahSalt Lake City, United States
- University of WashingtonSeattle, United States
- Washington University in St. LouisSt Louis, United States
- University of Arizona Sarver Heart CenterTucson, United States
- Medstar Washington Hospital Center (DC)Washington D.C., United States
About the trial
What the trial wants to find out
The aims of the DCM Precision Medicine Study are to test the hypothesis that DCM has substantial genetic basis and to evaluate the effectiveness of a family communication intervention in improving the uptake and impact of family member clinical screening.
The 2 groups in the trial
- Communication ToolTreatment being tested
Treatment: Family Heart Talk Booklet
- No Communication ToolNo study treatment, for comparison
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Precision Medicine for Dilated Cardiomyopathy in European and African Ancestry
- Publications
- Evaluation of Women With Peripartum or Dilated Cardiomyopathy and Their First-Degree Relatives: The DCM Precision Medicine Study.Circulation. Genomic and precision medicine, 2026
- Antecedent Flu-Like Illness and Onset of Idiopathic Dilated Cardiomyopathy: The DCM Precision Medicine Study.Circulation. Heart failure, 2025
- Alcohol Exposure Among Patients With Dilated Cardiomyopathy and Their First-Degree Relatives: The DCM Precision Medicine Study.Circulation. Genomic and precision medicine, 2025
- Rare Variant Genetics and Dilated Cardiomyopathy Severity: The DCM Precision Medicine Study.Circulation, 2023
- Differences in Cardiac Mechanics among Genetically At-Risk First-Degree Relatives: The DCM Precision Medicine Study.medRxiv : the preprint server for health sciences, 2023
- Effectiveness of the Family Heart Talk Communication Tool in Improving Family Member Screening for Dilated Cardiomyopathy: Results of a Randomized Trial.Circulation, 2023
- Validating an Idiopathic Dilated Cardiomyopathy Diagnosis Using Cardiovascular Magnetic Resonance: The Dilated Cardiomyopathy Precision Medicine Study.Circulation. Heart failure, 2022
- Prevalence and Cumulative Risk of Familial Idiopathic Dilated Cardiomyopathy.JAMA, 2022
- Variant Interpretation for Dilated Cardiomyopathy: Refinement of the American College of Medical Genetics and Genomics/ClinGen Guidelines for the DCM Precision Medicine Study.Circulation. Genomic and precision medicine, 2020
- Toward Genetics-Driven Early Intervention in Dilated Cardiomyopathy: Design and Implementation of the DCM Precision Medicine Study.Circulation. Cardiovascular genetics, 2017
- Record updated
- 30 July 2025